JPRN-UMIN000015057
Completed
未知
Investigation of metabolic change by SGLT2 inhibitors in type 2 diabetes patients. - Metabolic change by SGLT2 inhibitors.
Kitasato University School of Medicine,Endocrinology and Metabolism.0 sites20 target enrollmentSeptember 4, 2014
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kitasato University School of Medicine,Endocrinology and Metabolism.
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. severe ketosis, diabetic coma, or before coma 2\. before and not long after surgery,or patients with severe trauma 3\. alcohol intake's excessive 4\. patients who have a fever of 37\.0 degrees or more 5\. obvious infection 6\. severe renal dysfunction or dialysis patients 7\. patients with symptoms of urinary retention, difficulty urinating, anuria, or oliguria 8\. severe liver dysfunction 9\. patients with obvious active malignant tumor 10\. women suspected of pregnancy or pregnant 11\. patients with a history of use SGLT2 inhibitors
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Observational Study of the effect of SGLT2 inhibitor on Glycemic Control Indicesdiabetes mellitusJPRN-UMIN000050228agoya University4,250
Completed
Not Applicable
Effect of SGLT2 inhibitor on energy metabolism in patients with type 2 diabetesType 2 diabetesJPRN-UMIN000024822Kyoto University Graduate School of Medicine100
Not yet recruiting
Not Applicable
Effects of a SGLT2 inhibitor on glucose metabolism and body composition in patients with type 2 diabetesType 2 diabetes mellitusJPRN-UMIN000015402Department of Diabetes and Endocrinology Kobe City Medical Center General Hospital30
Completed
Phase 4
Glucose absorption inhibitors given during insulin withdrawal in type 1 and type3c diabetesISRCTN16404006niversity of Leicester12
Active, not recruiting
Phase 1
The REFORM TrialType 2 diabetes and Heart FailureTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2014-002742-42-GBniversity of Dundee/ NHS Tayside56